Talazoparib - BMN 673 | LT 00673

Based on 243 reference(s) in Google Scholar 10 10 243

Axon 2502

CAS [1207456-01-6]

MF C19H14F2N6O
MW 380.35

Purity: 99%
Optical purity: Optically pure
Soluble in DMSO

Talazoparib

Description

Potent, selective, and orally available PARP1/2 inhibitor (IC50 value 0.57 nM for PARP1) that shows antitumor cytotoxicity with 20- to more than 200-fold greater potency than earlier-generation PARP1/2 inhibitors and with selectivity for tumor cells with BRCA1, BRCA2, or PTEN gene defects.

M.A. Smith et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2015 Feb 15;21(4):819-32.

Y. Shen et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013 Sep 15;19(18):5003-15.

Potent, selective, and orally available PARP1/2 inhibitor

Chemical name

(8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one

Parent CAS No.

[1207456-01-6]

产品资料